346 related articles for article (PubMed ID: 28603207)
1. [Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6].
Okiyama N; Tanaka R
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):95-101. PubMed ID: 28603207
[TBL] [Abstract][Full Text] [Related]
2. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma.
Yano S; Ashida K; Nagata H; Ohe K; Wada N; Takeichi Y; Hanada Y; Ibayashi Y; Wang L; Sakamoto S; Sakamoto R; Uchi H; Shiratsuchi M; Furue M; Nomura M; Ogawa Y
BMC Endocr Disord; 2018 Jun; 18(1):36. PubMed ID: 29884162
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report.
Tanaka R; Maruyama H; Tomidokoro Y; Yanagiha K; Hirabayashi T; Ishii A; Okune M; Inoue S; Sekine I; Tamaoka A; Fujimoto M
Jpn J Clin Oncol; 2016 Sep; 46(9):875-8. PubMed ID: 27380808
[TBL] [Abstract][Full Text] [Related]
5. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
6. Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity.
Tanaka R; Okiyama N; Okune M; Ishitsuka Y; Watanabe R; Furuta J; Ohtsuka M; Otsuka A; Maruyama H; Fujisawa Y; Fujimoto M
J Dermatol Sci; 2017 Apr; 86(1):71-73. PubMed ID: 28069323
[No Abstract] [Full Text] [Related]
7. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
Godwin JL; Jaggi S; Sirisena I; Sharda P; Rao AD; Mehra R; Veloski C
J Immunother Cancer; 2017; 5():40. PubMed ID: 28515940
[TBL] [Abstract][Full Text] [Related]
8. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
9. Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Yamauchi I; Yasoda A; Matsumoto S; Sakamori Y; Kim YH; Nomura M; Otsuka A; Yamasaki T; Saito R; Kitamura M; Kitawaki T; Hishizawa M; Kawaguchi-Sakita N; Fujii T; Taura D; Sone M; Inagaki N
PLoS One; 2019; 14(5):e0216954. PubMed ID: 31086392
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab-induced thyroid dysfunction.
Tanaka R; Fujisawa Y; Maruyama H; Nakamura Y; Yoshino K; Ohtsuka M; Fujimoto M
Jpn J Clin Oncol; 2016 Jun; 46(6):575-9. PubMed ID: 27012985
[TBL] [Abstract][Full Text] [Related]
11. Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism.
Win MA; Thein KZ; Qdaisat A; Yeung SJ
Am J Emerg Med; 2017 Jul; 35(7):1039.e5-1039.e7. PubMed ID: 28363614
[TBL] [Abstract][Full Text] [Related]
12. Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report.
Narumi Y; Yoshida R; Minami Y; Yamamoto Y; Takeguchi S; Kano K; Takahashi K; Saito T; Sawada J; Terui H; Katayama T; Sasaki T; Ohsaki Y
BMC Cancer; 2018 Jan; 18(1):95. PubMed ID: 29361915
[TBL] [Abstract][Full Text] [Related]
13. Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma.
Seervai RNH; Heberton M; Cho WC; Gill P; Murphy MB; Aung PP; Nagarajan P; Torres-Cabala CA; Patel AB; Ruiz-Bañobre J; Om A; Yamamoto T; Nikolaou V; Curry JL
J Cutan Pathol; 2022 May; 49(5):472-481. PubMed ID: 34888886
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
[TBL] [Abstract][Full Text] [Related]
15. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab.
Fujisawa Y; Yoshino K; Otsuka A; Funakoshi T; Fujimura T; Yamamoto Y; Hata H; Gosho M; Tanaka R; Yamaguchi K; Nonomura Y; Hirai I; Furudate S; Okuhira H; Imafuku K; Aoki M; Matsushita S
J Dermatol Sci; 2017 Nov; 88(2):225-231. PubMed ID: 28736218
[TBL] [Abstract][Full Text] [Related]
16. PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses.
Medina PJ; Adams VR
Pharmacotherapy; 2016 Mar; 36(3):317-34. PubMed ID: 26822752
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic overlap of psoriasis, eczema, and psoriasiform dermatoses: A retrospective study of T helper type 2 and 17 subsets, interleukin 36, and β-defensin 2 in spongiotic psoriasiform dermatitis, sebopsoriasis, and tumor necrosis factor α inhibitor-associated dermatitis.
Cohen JN; Bowman S; Laszik ZG; North JP
J Am Acad Dermatol; 2020 Feb; 82(2):430-439. PubMed ID: 31859047
[TBL] [Abstract][Full Text] [Related]
18. Interstitial granulomatous dermatitis and granulomatous arteritis in the setting of PD-1 inhibitor therapy for metastatic melanoma.
Singh P; Wolfe SP; Alloo A; Gottesman SP
J Cutan Pathol; 2020 Jan; 47(1):65-69. PubMed ID: 31390071
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review.
Gauci ML; Laly P; Vidal-Trecan T; Baroudjian B; Gottlieb J; Madjlessi-Ezra N; Da Meda L; Madelaine-Chambrin I; Bagot M; Basset-Seguin N; Pages C; Mourah S; Boudou P; Lebbé C; Gautier JF
Cancer Immunol Immunother; 2017 Nov; 66(11):1399-1410. PubMed ID: 28634815
[TBL] [Abstract][Full Text] [Related]
20. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient.
Kanno H; Ishida K; Yamada W; Nishida T; Takahashi N; Mochizuki K; Mizuno Y; Matsuyama K; Takahashi T; Seishima M
J Infect Chemother; 2017 Nov; 23(11):774-777. PubMed ID: 28527652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]